Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Fosamprenavir calcium
Drug ID BADD_D00961
Description Fosamprenavir is a prodrug of amprenavir, an inhibitor of human immunodeficiency virus (HIV) protease.
Indications and Usage Indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (HIV-1) infection, as well as postexposure prophylaxis of HIV infection in individuals who have had occupational or nonoccupational exposure to potentially infectious body fluids of a person known to be infected with HIV when that exposure represents a substantial risk for HIV transmission. The use of fosamprenavir is pending revision due to a potential association between the drug and myocardial infarction and dyslipidemia in HIV infected adults.
Marketing Status approved
ATC Code J05AE07
DrugBank ID DB01319
KEGG ID D03835
MeSH ID C426859
PubChem ID 131535
TTD Drug ID D0F5MT
NDC Product Code 49702-208; 65015-806; 49702-207; 63379-087; 63304-583; 0378-3520
UNII ID1GU2627N
Synonyms fosamprenavir | fos-amprenavir | (3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-1-(phenylmethyl)-2-(phosphonooxy)propyl)carbamic acid C-(tetrahydro-3-furanyl) ester | VX-175 | VX 175 | GW-433908 | GW 908 | GW433908 | GW 433908 | GW-908 | fosamprenavir sodium | GW 433908A | GW-433908A | fosamprenavir calcium | Telzir | GW 433908G | GW-433908G | GW433908G | Lexiva
Chemical Information
Molecular Formula C25H34CaN3O9PS
CAS Registry Number 226700-81-8
SMILES CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OC2CCOC2)OP(=O)([O-])[O-])S(=O)(=O)C3=CC=C(C=C3) N.[Ca+2]
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain07.01.05.002--
Alanine aminotransferase increased13.03.04.005--
Angioedema10.01.05.009; 22.04.02.008; 23.04.01.001---
Aspartate aminotransferase increased13.03.04.011--
Asthenia08.01.01.001---
Blood cholesterol increased13.12.01.002--
Blood triglycerides increased13.12.03.001---
Body temperature increased13.15.01.001---
Breast enlargement21.05.04.001---
Dermatitis23.03.04.002---
Diabetes mellitus05.06.01.001; 14.06.01.001---
Diarrhoea07.02.01.001--
Dizziness02.11.04.006; 17.02.05.003; 24.06.02.007--
Drug hypersensitivity10.01.01.001---
Erythema multiforme10.01.03.015; 23.03.01.003--
Fatigue08.01.01.002--
Flatulence07.01.04.002--
Gastritis07.08.02.001--
Gastrooesophageal reflux disease07.02.02.003--
Gastrointestinal disorder07.11.01.001---
Gastrointestinal pain07.01.05.005--
Haemoglobin13.01.05.018---
Headache17.14.01.001--
Hypercholesterolaemia14.08.01.001---
Hyperglycaemia05.06.02.002; 14.06.02.002--
Hyperlactacidaemia14.01.01.006---
Hypersensitivity10.01.03.003--
Hypertriglyceridaemia14.08.02.001--
Immune system disorder10.02.01.001---
Insulin resistance05.06.02.003; 14.06.02.003---
The 1th Page    1 2 3    Next   Last    Total 3 Pages